



EXHIBIT A

PENDING CLAIMS FOR U.S. SERIAL NO. 09/822,110, WANG

1. (Amended) An isolated peptide of from 9 to about 70 amino acids in length, said peptide comprising [at least a first contiguous] the amino acid sequence [according to] of any one of SEQ ID NO:3 through SEQ ID NO:76.
2. (Original) The isolated peptide of claim 1, of from 9 to about 60 amino acids in length.
3. (Original) The isolated peptide of claim 2, of from 9 to about 50 amino acids in length.
4. (Original) The isolated peptide of claim 3, of from 9 to about 40 amino acids in length.
5. (Original) The isolated peptide of claim 4, of from 9 to about 30 amino acids in length.
6. (Original) The isolated peptide of claim 5, of from 9 to about 20 amino acids in length.
7. (Twice Amended) The isolated peptide of claim 1, said peptide comprising [a first contiguous] the amino acid sequence [selected from the group consisting] of SEQ ID NO:3, SEQ ID NO:4, [and] or SEQ ID NO:5.

8. (Amended) The isolated peptide of claim 1, said peptide consisting essentially of [a contiguous] the amino acid sequence [according to] of any one of SEQ ID NO:3 through SEQ ID NO:76.
9. (Amended) The isolated peptide of claim 8, said peptide consisting of [a contiguous] the amino acid sequence [according to] of any one of SEQ ID NO:3 through SEQ ID NO:76.
12. (Amended) An [The] isolated polypeptide [of claim 11,] consisting of the amino acid sequence from position 1 to position 322 of SEQ ID NO:2.
32. (Twice Amended) The isolated peptide of claim 1, or the polypeptide of claim 11, further comprising at least a first detectable label.
33. (Twice Amended) The isolated peptide or polypeptide of claim 32, wherein said at least a first detectable label is a radiolabel, a chromogenic label, a fluorescent label or a labelled secondary antibody that specifically binds to said peptide[,] or said polypeptide[, or said antibody].
34. (Twice Amended) The isolated peptide or polypeptide of claim 33, wherein said radiolabel comprises an ^3H , a ^{14}C , a ^{32}P , a ^{35}S , a ^{90}Y , a ^{99}Tc , an ^{125}I , or an ^{131}I label.
35. (Twice Amended) The isolated peptide or polypeptide of claim 33, wherein said chromogenic label comprises alkaline phosphatase, peroxidase, β -glucuronidase, β -D-

glucosidase, β -D-galactosidase, urease, glucose oxidase/oxidase, or galactose oxidase/oxidase.

36. (Twice Amended) The isolated peptide or polypeptide of claim 33, wherein said fluorescent label comprises a fluorescent protein, fluorescein, rhodamine, or auramine.
37. (Amended) The isolated peptide or polypeptide of claim 36, wherein said fluorescent protein comprises at least a first green fluorescent protein or at least a first humanized green fluorescent protein.
42. (Twice Amended) A composition comprising: the isolated peptide of claim 1, or the polypeptide of claim 11.
43. (Original) The composition of claim 42, further comprising at least a first pharmaceutically-acceptable excipient.
44. (Original) The composition ~~of claim 42~~, further comprising at least a first immunostimulant or at least a first adjuvant.
45. (Original) The composition of claim 44, wherein said at least a first immunostimulant or said at least a first adjuvant is selected from the group consisting of a cytokine, a microsphere, Ribi Adjuvant, saponin, a microfluidized adjuvant, an immune stimulating complex, and an inactivated toxin.

46. (Original) The composition of claim 42, wherein said composition is formulated for parenteral, intravenous, intraperitoneal, subcutaneous, intranasal, transdermal, or oral administration to an animal.
47. (Original) The composition of claim 42, further comprising at least a first detection reagent.
48. (Original) The composition of claim 47, wherein said detection reagent comprises a radiolabel, a spin label, or a fluorogenic, chromogenic, or a chemiluminescent label.
49. (Amended) The composition of claim 48, wherein said at least a first detection reagent specifically binds to (a) a p33^{QIK} peptide or polypeptide; (b) a p63^{Krs1} peptide or polypeptide, [or to] (c) an antibody or an antigen binding fragment specific for a p33^{QIK} peptide or polypeptide, or (d) an antibody or an antigen binding fragment specific for a p63^{Krs1} peptide or polypeptide.
50. (Twice Amended) A kit comprising the isolated peptide of claim 1, the isolated polypeptide of claim-11, or an antibody or an antigen binding fragment specific for either the isolated peptide of claim 1 or the isolated polypeptide of claim-11; and instructions for using said kit.
51. (Original) The kit of claim 50, wherein said kit comprises at least one component for performing immunoprecipitation, a dot blot, an ELISA, an RIA, or a Western blot.

52. (Amended) The kit of claim 50, wherein said kit comprises at least one component for immunoprecipitating [a native or biologically-active mammalian p33^{QIK} or p63^{Krs1}] an antibody or an antigen binding fragment specific for a p33^{QIK} peptide or polypeptide or a p63^{Krs1} peptide or polypeptide from a sample.
61. (New) The isolated peptide of claim 7, said peptide comprising the amino acid sequence of SEQ ID NO:3.
62. (New) The isolated peptide of claim 7, said peptide comprising the amino acid sequence of SEQ ID NO:4.
63. (New) The isolated peptide of claim 7, said peptide comprising the amino acid sequence of SEQ ID NO:5.
64. (New) An isolated peptide of from 14 to about 70 amino acids in length, said peptide comprising the sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.
65. (New) An isolated peptide of from 14 to about 70 amino acids in length, said peptide consisting essentially of the sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.
66. (New) An isolated peptide consisting of the sequence of any one of SEQ ID NO:3 through SEQ ID NO:76.

67. (New) An isolated peptide of from 14 to about 50 amino acids in length, said peptide comprising the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.
68. (New) The isolated peptide of claim 67, wherein said peptide is from 14 to about 45 amino acids in length.
69. (New) The isolated peptide of claim 67, wherein said peptide is from 14 to about 40 amino acids in length.
70. (New) The isolated peptide of claim 67, wherein said peptide is from 14 to about 35 amino acids in length.
71. (New) The isolated peptide of claim 67, wherein said peptide is from 14 to about 30 amino acids in length.
72. (New) The isolated peptide of claim 67, wherein said peptide is from 14 to about 25 amino acids in length.
73. (New) An isolated peptide of from 14 to about 70 amino acids in length, said peptide comprising an amino acid sequence selected from any one of SEQ ID NO:3 through SEQ ID NO:76.

74. (New) An isolated peptide of from 14 to about 60 amino acids in length, said peptide comprising an amino acid sequence selected from any one of SEQ ID NO:3 through SEQ ID NO:76.
75. (New) An isolated peptide of from 14 to about 50 amino acids in length, said peptide comprising an amino acid sequence selected from any one of SEQ ID NO:3 through SEQ ID NO:76.